Allegiance Financial Group Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Allegiance Financial Group Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,867	Closed	-$218K	–	210
2026 Q1	$218K	Buy	+3,867	New	+$225K	0.04%	177
2025 Q4	–	Sell	-3,774	Closed	-$204K	–	182
2025 Q3	$204K	Buy	+3,774	New	+$216K	0.05%	157
2025 Q2	–	Sell	-3,063	Closed	-$217K	–	159
2025 Q1	$217K	Buy	+3,063	New	+$206K	0.07%	122

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Allegiance Financial Group Advisory Services's BMRN Position: Q2 2026 in Review

Allegiance Financial Group Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 3,867 shares — an estimated $218K sold.

Allegiance Financial Group Advisory Services first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $218K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Allegiance Financial Group Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Allegiance Financial Group Advisory Services sold 3,867 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $218K.
Allegiance Financial Group Advisory Services first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Allegiance Financial Group Advisory Services's BioMarin Pharmaceuticals position peaked at $218K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Allegiance Financial Group Advisory Services's 13F filing for Q2 2026, filed 27 Jul 2026.